On Monday "Clinical Care Options" released this comprehensive webinar; Practice-Changing Advances From EASL 2015, with Dr. Mark Sulkowski discussing the following topics; HCV therapy in the setting of renal impairment, resistance testing in DAA experienced patients, and the best approach to treat patients with cirrhosis or experienced patients who have genotype 3 infection.
EASL Highlights
Downloadable slides: Investigational agents and approved HCV therapies
This downloadable slideset summarizes key studies selected by Andrew J. Muir, MD, David R. Nelson, MD, and Norah Terrault, MD, MPH, regarding the use of investigational agents for treating hepatitis C presented at the 2015 Annual Meeting of the European Association for the Study of the Liver.
Date Posted: 5/12/2015
Highlights From EASL: HCV Approved Therapies
In this downloadable slideset, Jordan J. Feld, MD, MPH; Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, FAASLD; and Stefan Zeuzem, MD, review key studies on currently approved HCV therapies presented at the 2015 Annual Meeting of the European Association for the Study of the Liver.
Date Posted: 5/11/2015
Free registration is required
Date Posted: 5/12/2015
Highlights From EASL: HCV Approved Therapies
In this downloadable slideset, Jordan J. Feld, MD, MPH; Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, FAASLD; and Stefan Zeuzem, MD, review key studies on currently approved HCV therapies presented at the 2015 Annual Meeting of the European Association for the Study of the Liver.
Date Posted: 5/11/2015
Free registration is required
Thanks for the links and file. As a patient I never take part in these activities but I learned so much by listening to the presentation.
ReplyDelete